Synergistic interaction between ouabain and 8-methoxy-3,9-dihydroxy coumestan, a non-steroidal synthetic inhibitor of Na+,K+-ATPase

Life Sciences

Volumn 81, Issue 15, 2007, Pages 1199-1204

  Pôças, Elisa Suzana Carneiro ^a,b   Touza, Natália Araújo ^a   da Silva, Alcides J M ^a   Costa, Paulo R R ^a   Noël, François ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

Author keywords

Additivity; ATPase, Na K; Coumestan; Ouabagenin; Ouabain; Synergism; Wedelolactone

Indexed keywords

8 METHOXY 3,9 DIHYDROXYCOUMESTAN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; CARDIAC GLYCOSIDE; LQB 93; OUABAGENIN; OUABAIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; DRUG BINDING SITE; DRUG POTENTIATION; ENZYME INHIBITION; IC 50; ISOBOLOGRAPHIC ANALYSIS; NONHUMAN; RAT; THEORETICAL STUDY;

ANIMALS; BENZOFURANS; BINDING SITES; COUMARINS; DRUG SYNERGISM; ENZYME INHIBITORS; KIDNEY; MALE; OUABAIN; RATS; RATS, WISTAR; SODIUM-POTASSIUM-EXCHANGING ATPASE;

RATTUS; STROPHANTHUS GRATUS;

EID: 34848867153     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.08.021     Document Type: Article

References (22)

1. Bell A. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiology Letters 253 (2005) 171-184
2. Berembaum M.C. What is synergy?. Pharmacological Reviews 41 2 (1989) 93-141
3. +-ATPase. Journal of Medicinal Chemistry 45 (2002) 189-207
4. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 58 3 (2006) 621-681
5. Gobbini M., Barassi P., Cerri A., De Munari S., Fedrizzi G., Santagostino M., Schiavone A., Torri M., and Melloni P. 17r-O-(aminoalkyl)oxime derivatives of 3,14-dihydroxy-5,-androstane and 3-hydroxy-14-oxoseco-d-5-androstane as inhibitors of Na+,K+-ATPase at the digitalis receptor. Journal of Medicinal Chemistry 44 (2001) 3821-3830
6. Gottlieb S.S., Rogowski A.C., Weinberg M., Krichten C.M., Hamilton B.P., and Hamlyn J.M. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86 2 (1992) 420-425
7. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacological Reviews 47 2 (1995) 331-385
8. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193 (1951) 265-275
9. Manunta P., Stella P., Rivera R., Ciurlino D., Cusi D., Ferrandi M., Hamlyn J.M., and Bianchi G. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34 3 (1999) 450-456
10. Nesher M., Shpolansky U., Rosen H., and Lichtstein D. The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sciences 80 (2007) 2093-2107
11. +-ATPase inhibition in microsomes from rat heart. Biochemical Pharmacology 33 (1984) 47-53
12. +)-ATPase isozymes for cardioactive steroids, role of lactone ring, sugar moiety and KCl concentration. Biochemical Pharmacology 40 (1990) 2611-2616
13. + 2. Life Sciences 44 22 (1989) 1677-1683
14. Pitzalis M.V., Hamlyn J.M., Messaggio E., Iacoviello M., Forleo C., Romito R., de Tommasi E., Rizzon P., Bianchi G., and Manunta P. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. European Journal of Heart Failure 8 2 (2006) 179-186
15. +-ATPase with an original mechanism of action. Biochemical Pharmacology 66 (2003) 2169-2176
16. Pôças E.S.C., Lopes D.V.S., da Silva A.J.M., Pimenta P.H.C., Leitão F.B., Netto C.D., Buarque C.D., Brito F.V., Costa P.R.R., and Noël F. Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+,K+-ATPase and binding to the central benzodiazepine receptor. Bioorganic Medicinal Chemistry 14 (2006) 7962-7966
17. Repke K.R.H., Sweadner K.J., Weiland J., Megges R., and Schön R. In search of ideal inotropic steroids: recent progress. Progress in Drug Research 47 (1996) 9-52
18. Sevillano L.G., Melero C.P., Caballero E., Tomé F., Lelièvre L.G., Geering K., Crambert G., Carrón R., Medarde M., and San Feliciano A. Inotropic activity of hydroindene amidinohydrazones. Journal of Medicinal Chemistry 45 (2002) 127-136
19. Tallarida R.J. Drug synergism: its detection and applications. Journal of Pharmacology and Experimental Therapeutics 298 3 (2001) 865-872
20. Tallarida R.J. An overview of drug combination analysis with isobolograms. Journal of Pharmacology and Experimental Therapeutics 319 1 (2006) 1-7
21. Tallarida R.J., Stone Jr. D.J., and Raffa R.B. Efficient designs for studying synergistic drug combinations. Life Sciences 61 26 (1997) 417-425
22. Zar J.H. Biostatistical Analysis. third ed. (1996), Prentice-Hall, Upper Saddle River, New Jersey (chapter 17)